Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental 'Alarm' therapy aims to rev up immune system against Hard-to-Treat cancers

NCT ID NCT05338658

Recruiting now Disease control Sponsor: Masonic Cancer Center, University of Minnesota Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new approach called Peptide Alarm Therapy (PAT) for people with advanced solid tumors that have not responded to at least one prior treatment, including immunotherapy. PAT is injected directly into a tumor along with a standard PD-1 inhibitor drug. The goal is to see if this combination is safe and can help shrink or control the cancer. Only 21 participants who have certain immune markers (CMV and EBV positive, and a specific HLA type) will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Peptide Alarm Therapy (PAT) combined with pembrolizumab (a PD-1 inhibitor)
What this could lead to
If it works, this could offer a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong
This is a very early Phase I trial with only 21 participants, so it is too soon to know if it will be safe or effective. The treatment is given directly into tumors and may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic neoplasm neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTASIS SOLID TUMOR

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Masonic Cancer Center at University of Minnesota

    RECRUITING

    Minneapolis, Minnesota, 55455, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.